First-line bevacizumab plus taxane-based chemotherapy for
locally recurrent or metastatic breast cancer: safety and
efficacy in an open-label study in 2,251 patients

J 2011

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients

SMITH, I. E.; J. Y. PIERGA; L. BIGANZOLI; H. CORTES-FUNES; C. THOMSSEN et al.

Základní údaje

Originální název

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients

Autoři

Vydání

Annals of Oncology, Oxford, Oxford University Press, 2011, 0923-7534

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 6.425

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/11:00055219

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1093/annonc/mdq430

UT WoS

000287750700014

Klíčová slova anglicky

angiogenesis; bevacizumab; first-line; metastatic breast cancer

Příznaky

Mezinárodní význam

Změněno: 20. 4. 2012 12:10, Mgr. Michal Petr

Anotace

V originále

First-line bevacizumab combined with chemotherapy significantly improves efficacy versus chemotherapy alone in human epidermal growth factor receptor 2 (HER2)-negative locally recurrent or metastatic breast cancer (LR/mBC). This large, open-label study further assesses first-line bevacizumab with taxane-based chemotherapy in routine oncology practice. Patients and methods: Patients with HER2-negative LR/mBC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of zero to two and no prior chemotherapy for LR/mBC received bevacizumab 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks plus taxane-based chemotherapy (or other non-anthracycline chemotherapy) until disease progression, unacceptable toxicity or patient withdrawal. The primary end point was safety; time to progression (TtP) was a secondary end point. Results: Median follow-up in 2251 treated patients was 12.7 months. Median age was 53 years and 94% of patients had ECOG PS of zero or one. Bevacizumab was most commonly administered with single-agent paclitaxel (35%), single-agent docetaxel (33%) or taxane-based combination therapy (10%). The most frequent grade >= 3 adverse event (AE) was neutropenia (5.4%). Grade >= 3 AEs previously associated with bevacizumab included hypertension (4.4%), arterial/venous thromboembolism (3.2%), proteinuria (1.7%) and bleeding (1.4%). No new bevacizumab safety signals were observed. Median TtP was 9.5 months (95% confidence interval 9.1-9.9). Conclusions: The study population in ATHENA was more representative of general oncology practice than populations enrolled into randomised trials, although there may have been some bias towards younger, fitter patients. The safety and efficacy of bevacizumab-taxane therapy in this large study were consistent with results from randomised first-line trials.

Citovat

SMITH, I. E.; J. Y. PIERGA; L. BIGANZOLI; H. CORTES-FUNES; C. THOMSSEN; X. PIVOT; A. FABI; B. XU; D. STROYAKOVSKIY; F.A. FRANKE; B. KAUFMAN; P. MAINWARING; T. PIENKOWSKI; B. DE VALK; A. KWONG; J.L. GONZALEZ-TRUJILLO; I. KOZA; Katarína PETRÁKOVÁ; D. PEREIRA a K.I. PRITCHARD. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Annals of Oncology. Oxford: Oxford University Press, 2011, roč. 22, č. 3, s. 595-602. ISSN 0923-7534. Dostupné z: https://doi.org/10.1093/annonc/mdq430.

@article{968959,
   author = {Smith, I. E. and Pierga, J. Y. and Biganzoli, L. and CortesandFunes, H. and Thomssen, C. and Pivot, X. and Fabi, A. and Xu, B. and Stroyakovskiy, D. and Franke, F.A. and Kaufman, B. and Mainwaring, P. and Pienkowski, T. and De Valk, B. and Kwong, A. and GonzalezandTrujillo, J.L. and Koza, I. and Petráková, Katarína and Pereira, D. and Pritchard, K.I.},
   article_location = {Oxford},
   article_number = {3},
   doi = {https://doi.org/10.1093/annonc/mdq430},
   keywords = {angiogenesis; bevacizumab; first-line; metastatic breast cancer},
   language = {eng},
   issn = {0923-7534},
   journal = {Annals of Oncology},
   title = {First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients},
   volume = {22},
   year = {2011}
}

TY  - JOUR
ID  - 968959
AU  - Smith, I. E. - Pierga, J. Y. - Biganzoli, L. - Cortes-Funes, H. - Thomssen, C. - Pivot, X. - Fabi, A. - Xu, B. - Stroyakovskiy, D. - Franke, F.A. - Kaufman, B. - Mainwaring, P. - Pienkowski, T. - De Valk, B. - Kwong, A. - Gonzalez-Trujillo, J.L. - Koza, I. - Petráková, Katarína - Pereira, D. - Pritchard, K.I.
PY  - 2011
TI  - First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients
JF  - Annals of Oncology
VL  - 22
IS  - 3
SP  - 595-602
EP  - 595-602
PB  - Oxford University Press
SN  - 09237534
KW  - angiogenesis
KW  - bevacizumab
KW  - first-line
KW  - metastatic breast cancer
N2  - First-line bevacizumab combined with chemotherapy significantly improves efficacy versus chemotherapy alone in human epidermal growth factor receptor 2 (HER2)-negative locally recurrent or metastatic breast cancer (LR/mBC). This large, open-label study further assesses first-line bevacizumab with taxane-based chemotherapy in routine oncology practice. Patients and methods: Patients with HER2-negative LR/mBC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of zero to two and no prior chemotherapy for LR/mBC received bevacizumab 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks plus taxane-based chemotherapy (or other non-anthracycline chemotherapy) until disease progression, unacceptable toxicity or patient withdrawal. The primary end point was safety; time to progression (TtP) was a secondary end point. Results: Median follow-up in 2251 treated patients was 12.7 months. Median age was 53 years and 94% of patients had ECOG PS of zero or one. Bevacizumab was most commonly administered with single-agent paclitaxel (35%), single-agent docetaxel (33%) or taxane-based combination therapy (10%). The most frequent grade >= 3 adverse event (AE) was neutropenia (5.4%). Grade >= 3 AEs previously associated with bevacizumab included hypertension (4.4%), arterial/venous thromboembolism (3.2%), proteinuria (1.7%) and bleeding (1.4%). No new bevacizumab safety signals were observed. Median TtP was 9.5 months (95% confidence interval 9.1-9.9). Conclusions: The study population in ATHENA was more representative of general oncology practice than populations enrolled into randomised trials, although there may have been some bias towards younger, fitter patients. The safety and efficacy of bevacizumab-taxane therapy in this large study were consistent with results from randomised first-line trials.
ER  -

SMITH, I. E.; J. Y. PIERGA; L. BIGANZOLI; H. CORTES-FUNES; C. THOMSSEN; X. PIVOT; A. FABI; B. XU; D. STROYAKOVSKIY; F.A. FRANKE; B. KAUFMAN; P. MAINWARING; T. PIENKOWSKI; B. DE VALK; A. KWONG; J.L. GONZALEZ-TRUJILLO; I. KOZA; Katarína PETRÁKOVÁ; D. PEREIRA a K.I. PRITCHARD. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. \textit{Annals of Oncology}. Oxford: Oxford University Press, 2011, roč.~22, č.~3, s.~595-602. ISSN~0923-7534. Dostupné z: https://doi.org/10.1093/annonc/mdq430.

Přehled o publikaci